B. Riley starts coverage on Arcturus Therapeutics with Buy, praising its standout lipid-enabled mRNA platform for cystic fibrosis (ARCT-032) and OTC deficiency (ARCT-810) programs.
Roth Capital initiates coverage of Arcturus Therapeutics with a Buy rating and $20 price target, citing undervaluation and strong rare disease pipeline potential.
Arcturus Therapeutics shares drop sharply after interim trial data on its inhaled mRNA therapy for cystic fibrosis show mixed results—some signs of mucus reduction but limited lung function improvement.
